Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ChAdOx1 nCoV-19
- Development stage
- Phase 4
- Lead developer
- AstraZeneca
- Modality
- Viral Vector Vaccines → Recombinant Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
ChAdOx1 nCoV-19 is a viral vector vaccine developed by Oxford University and AstraZeneca against COVID-19. It utilizes a modified, replication-deficient chimpanzee adenovirus (ChAdOx1) to deliver the genetic code for the SARS-CoV-2 spike protein. This instructs host cells to produce the spike protein, thereby triggering an immune response and immunological memory. Administered as two intramuscular doses (0.5 mL each) typically 8-12 weeks apart, it is intended for adults aged 18 years and older. Clinical trials showed varying efficacy rates depending on dosing, with an overall efficacy of 63.1% or 70.4% in pooled analyses. The vaccine is authorized for use worldwide under various brand names including Vaxzevria and COVISHIELD.
- Brand names
- VaxzevriaCOVISHIELD
- Other names
- ChAdOx1 nCoV-19 Corona Virus Vaccine (Recombinant)COVID-19 Vaccine AstraZenecaCOVID19 Vaccine AstraZenecaCOVID 19 Vaccine AstraZeneca
02
Targets
SARS-CoV-2 spikeACE2 (Angiotensin-converting enzyme 2)
Beyond the preview
Go deeper on ChAdOx1 nCoV-19.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ChAdOx1 nCoV-19.